Yetkin Derya, Balli Ebru, Ayaz Furkan
Mersin University, Advanced Technology Education Research and Application Center, 33110, Mersin, Turkey.
Mersin University, Department of Histology and Embryology, 33110 Mersin, Turkey.
EXCLI J. 2021 Sep 21;20:1394-1406. doi: 10.17179/excli2021-3989. eCollection 2021.
Breast cancer stands out as the most common cancer type among women throughout the world. Especially for the estrogen receptor alpha (ER α +) positive breast cancer cells Tamoxifen has been widely used as an anti-cancer agent. Tamoxifen's mechanism of action is through ER. It binds to the receptor and leads to a conformational change which eventually prevents cancer cells proliferation and survival. In our current study, we aimed to investigate the combination of Tamoxifen with Vitamin D to test whether this combination will enhance the anti-cancer effect of Tamoxifen on breast cancer cells . Vitamin D has sterol structure and this property enables it to act similar to hormones. Vitamin D Receptor (VDR) has been commonly found in different types of cancer cells including but not limited to breast and prostate cancer cells. Through this receptor Vitamin D acts as an anti-proliferative agent. We examined the proliferation rate, apoptosis and necrosis levels as well as cell cycle progression in MCF-7 breast cancer cell line in the presence of Vitamin D and Tamoxifen to compare the changes with the Tamoxifen treated group. Our results suggest that Tamoxifen was a more potent anti-cancer agent than Vitamin D or its combination with Vitamin D based on cell cycle arrest, apoptosis and cell proliferation levels. This effect in the apoptosis rate and cell cycle stage of the MCF-7 cells were in line with the changes in gene expression profile of , and . Our results suggest that Tamoxifen by itself is adequate enough and more potent than Vitamin D or its combination with Vitamin D as anti-cancer agent for the breast cancer cells .
乳腺癌是全球女性中最常见的癌症类型。特别是对于雌激素受体α（ERα+）阳性乳腺癌细胞，他莫昔芬已被广泛用作抗癌药物。他莫昔芬的作用机制是通过ER。它与受体结合并导致构象变化，最终阻止癌细胞的增殖和存活。在我们目前的研究中，我们旨在研究他莫昔芬与维生素D的联合使用，以测试这种联合是否会增强他莫昔芬对乳腺癌细胞的抗癌作用。维生素D具有甾醇结构，这种特性使其能够像激素一样发挥作用。维生素D受体（VDR）常见于不同类型的癌细胞中，包括但不限于乳腺癌和前列腺癌细胞。通过这种受体，维生素D作为一种抗增殖剂发挥作用。我们在维生素D和他莫昔芬存在的情况下，检测了MCF-7乳腺癌细胞系的增殖率、凋亡和坏死水平以及细胞周期进程，以比较与他莫昔芬治疗组的变化。我们的结果表明，基于细胞周期阻滞、凋亡和细胞增殖水平，他莫昔芬是一种比维生素D或其与维生素D联合使用更有效的抗癌药物。MCF-7细胞凋亡率和细胞周期阶段的这种效应与 、 和 的基因表达谱变化一致。我们的结果表明，对于乳腺癌细胞，他莫昔芬本身就足够有效，并且比维生素D或其与维生素D联合使用更有效。
